1. [CASE 1 — QUESTION 1]
A 32-year-old man presents with fatigue, reduced libido, and erectile difficulties. Two fasting morning total testosterone measurements are 215 and 240 ng/dL, with low-normal LH and FSH, normal prolactin, and an unremarkable pituitary MRI. He and his wife have been trying to conceive for 10 months, and a semen analysis shows low-normal sperm concentration. He has read online that testosterone injections will "fix everything" and asks to start them today. Which of the following best explains why initiating exogenous testosterone replacement therapy (TRT) would be expected to impair his fertility?
A) Exogenous testosterone is directly toxic to developing sperm cells within the seminiferous tubules, killing germ cells on contact regardless of hormone levels.
B) Exogenous testosterone suppresses hypothalamic GnRH and pituitary LH and FSH secretion through negative feedback; the loss of LH-driven Leydig cell stimulation collapses intratesticular testosterone (which must be maintained far above serum levels to support spermatogenesis), and FSH suppression removes Sertoli cell support, producing oligospermia or azoospermia despite adequate serum testosterone.
C) Exogenous testosterone raises FSH while suppressing LH, and the elevated FSH directly destroys germ cells.
D) Exogenous testosterone increases sex hormone-binding globulin, lowering free testosterone within the testis and impairing sperm production through an SHBG-mediated mechanism.
E) Exogenous testosterone accelerates aromatization within the testis, and the resulting high local estradiol is the sole cause of impaired spermatogenesis.
ANSWER: B
Rationale:
Option B is correct. Exogenous testosterone raises serum testosterone but suppresses the hypothalamic-pituitary-gonadal axis through negative feedback: hypothalamic GnRH pulsatility and pituitary LH and FSH secretion fall. Because intratesticular testosterone — which must be maintained at roughly 50 to 100 times the serum concentration to support spermatogenesis — depends on LH-driven Leydig cell stimulation, the loss of LH drive collapses intratesticular testosterone below the spermatogenic threshold. Concurrent FSH suppression removes Sertoli cell support of germ cell development. The result is oligospermia or azoospermia in most men within 3 to 6 months, even though serum testosterone is adequate or elevated. This is why a man actively trying to conceive should not be started on TRT.
Option A: Option A is incorrect; exogenous testosterone does not directly kill germ cells on contact — the mechanism is feedback suppression of the intratesticular testosterone required for spermatogenesis.
Option C: Option C is incorrect; exogenous testosterone suppresses FSH rather than raising it, and FSH supports (not destroys) spermatogenesis.
Option D: Option D is incorrect; the impairment is not mediated by an SHBG-driven reduction of intratesticular free testosterone; it results from suppressed LH and collapsed intratesticular testosterone production.
Option E: Option E is incorrect; while some aromatization occurs, local estradiol is not the sole cause of impaired spermatogenesis — the dominant mechanism is HPG axis suppression collapsing intratesticular testosterone.
2. [CASE 1 — QUESTION 2]
Continuing with the same patient. After you explain the effect of testosterone replacement therapy on fertility, he agrees he wants to preserve his ability to conceive. Which of the following is the most appropriate pharmacologic approach to raise his testosterone while maintaining spermatogenesis?
A) Begin biweekly intramuscular testosterone enanthate but at a reduced dose, since low-dose injectable testosterone does not suppress the hypothalamic-pituitary-gonadal axis.
B) Begin transdermal testosterone gel, since transdermal delivery uniquely preserves spermatogenesis while raising serum testosterone.
C) Begin a GnRH agonist to stimulate the pituitary and increase both testosterone and sperm production.
D) Initiate clomiphene citrate (a selective estrogen receptor modulator that blocks hypothalamic estrogen receptor feedback to raise endogenous LH and FSH) or human chorionic gonadotropin (an LH-receptor agonist that maintains intratesticular testosterone), either of which raises testosterone while preserving spermatogenesis.
E) Begin an aromatase inhibitor as the sole therapy, since blocking estradiol production is sufficient to normalize both testosterone and fertility in all hypogonadal men.
ANSWER: D
Rationale:
Option D is correct. For a hypogonadal man who wishes to preserve fertility, the goal is to raise testosterone without suppressing the hypothalamic-pituitary-gonadal (HPG) axis. Clomiphene citrate, a selective estrogen receptor modulator, blocks estrogen receptor-mediated negative feedback at the hypothalamus, increasing endogenous LH and FSH and thereby raising testosterone while supporting spermatogenesis. Human chorionic gonadotropin acts as an LH-receptor agonist on Leydig cells to maintain high intratesticular testosterone (and can be combined with FSH if needed). Either approach raises testosterone while preserving sperm production, in contrast to exogenous testosterone.
Option A: Option A is incorrect; even low-dose injectable testosterone suppresses the HPG axis and impairs spermatogenesis — there is no "safe" exogenous testosterone dose that reliably preserves fertility.
Option B: Option B is incorrect; transdermal testosterone gel suppresses spermatogenesis just as other testosterone formulations do; the route does not protect fertility.
Option C: Option C is incorrect; a GnRH agonist causes an initial testosterone flare followed by pituitary downregulation and sustained gonadotropin and testosterone suppression — it is used for androgen deprivation, not fertility preservation.
Option E: Option E is incorrect; an aromatase inhibitor alone is not the standard fertility-preserving therapy and is not sufficient to normalize testosterone and fertility in all hypogonadal men; clomiphene or hCG are the established approaches.
3. [CASE 1 — QUESTION 3]
Continuing with the same patient. He is started on human chorionic gonadotropin (hCG). He asks how this medication works to raise his testosterone differently from a testosterone injection. Which of the following best describes the mechanism of hCG?
A) hCG structurally and functionally mimics luteinizing hormone (LH) and acts as an agonist at the LH receptor on testicular Leydig cells, directly stimulating intratesticular testosterone production without suppressing the hypothalamic-pituitary axis.
B) hCG blocks estrogen receptors at the hypothalamus, raising endogenous LH and FSH, which is identical to the mechanism of clomiphene.
C) hCG inhibits aromatase, preventing testosterone from being converted to estradiol and thereby raising testosterone levels.
D) hCG acts directly on Sertoli cells through the FSH receptor to stimulate testosterone synthesis.
E) hCG suppresses pituitary LH secretion, and the resulting fall in testosterone triggers a compensatory rebound that ultimately raises testosterone above baseline.
ANSWER: A
Rationale:
Option A is correct. Human chorionic gonadotropin shares structural and functional homology with luteinizing hormone (LH) and acts as an agonist at the LH receptor on testicular Leydig cells. By directly stimulating the Leydig cells, hCG maintains high intratesticular testosterone production without requiring an intact hypothalamic-pituitary axis and without the negative feedback suppression caused by exogenous testosterone — which is precisely why it preserves spermatogenesis while raising testosterone.
Option B: Option B is incorrect; blocking hypothalamic estrogen receptors to raise endogenous LH and FSH is the mechanism of clomiphene (a SERM), not hCG; hCG acts directly at the LH receptor.
Option C: Option C is incorrect; hCG does not inhibit aromatase; aromatase inhibition is a separate pharmacologic strategy.
Option D: Option D is incorrect; hCG acts at the LH receptor on Leydig cells, not at the FSH receptor on Sertoli cells; Sertoli cells do not synthesize testosterone.
Option E: Option E is incorrect; hCG stimulates rather than suppresses the testosterone-producing pathway, acting directly at the LH receptor — it does not work through a suppression-and-rebound mechanism.
4. [CASE 1 — QUESTION 4]
Continuing with the same patient. He responds well to therapy with improved symptoms. He mentions a friend who used high-dose anabolic steroids for years and then could not conceive for a long time after stopping. He asks what to expect regarding sperm recovery if a man has suppressed his axis with exogenous androgens. Which of the following statements about recovery of spermatogenesis after androgen-induced suppression is most accurate?
A) Recovery of spermatogenesis is instantaneous once exogenous androgen is stopped, typically within a few days, because the hypothalamic-pituitary-gonadal axis resumes immediately.
B) Spermatogenesis never recovers after any period of exogenous androgen suppression; azoospermia from androgen use is uniformly permanent.
C) Recovery of spermatogenesis after cessation of exogenous androgens typically takes 6 to 24 months and may be incomplete, particularly after prolonged or high-dose use; agents such as human chorionic gonadotropin and selective estrogen receptor modulators can be used to assist recovery of the hypothalamic-pituitary-gonadal axis.
D) Recovery depends solely on the patient's age and is unrelated to the dose or duration of androgen exposure.
E) Sperm production recovers fully within exactly 30 days in all men, regardless of the duration or dose of prior androgen use.
ANSWER: C
Rationale:
Option C is correct. After exogenous androgens (including testosterone replacement therapy and anabolic-androgenic steroids) suppress the hypothalamic-pituitary-gonadal (HPG) axis, recovery of spermatogenesis typically takes 6 to 24 months following cessation, and recovery may be incomplete, especially after prolonged or high-dose use. Recovery can be assisted pharmacologically with human chorionic gonadotropin (an LH-receptor agonist that restores intratesticular testosterone) and selective estrogen receptor modulators such as clomiphene (which raise endogenous LH and FSH).
Option A: Option A is incorrect; recovery is not instantaneous; the suppressed axis requires months to recover, not days.
Option B: Option B is incorrect; spermatogenesis is frequently recoverable after androgen-induced suppression, often aided by recovery pharmacology — it is not uniformly permanent.
Option D: Option D is incorrect; recovery is influenced by the dose and duration of androgen exposure (as well as other factors), not by age alone.
Option E: Option E is incorrect; full recovery does not occur in a fixed 30 days for all men; the timeline is months-long and variable, dependent on dose and duration.
5. [CASE 2 — QUESTION 5]
A 61-year-old man with type 2 diabetes, hypertension, and a prior myocardial infarction 2 years ago reports low energy, reduced libido, and depressed mood. His primary care physician is considering testosterone replacement therapy (TRT). A single afternoon total testosterone drawn at the initial visit is 280 ng/dL. Before committing to a diagnosis of hypogonadism, which of the following is the most appropriate step to confirm the diagnosis?
A) Begin TRT immediately based on the single afternoon testosterone value and his symptoms, as one low measurement is sufficient for diagnosis.
B) Diagnose hypogonadism on the basis of symptoms alone, without any biochemical confirmation, since symptoms are the definitive criterion.
C) Order a serum estradiol level as the confirmatory test, since estradiol is the primary determinant of the diagnosis of male hypogonadism.
D) Measure prolactin alone and, if normal, proceed directly to TRT without repeating the testosterone measurement.
E) Confirm the diagnosis with at least two fasting morning total testosterone measurements demonstrating consistently low values, because testosterone exhibits diurnal variation (peaking in the early morning) and a single non-morning measurement is insufficient; symptoms attributable to testosterone deficiency must also be present.
ANSWER: E
Rationale:
Option E is correct. The diagnosis of male hypogonadism requires both consistently low morning serum total testosterone and symptoms attributable to testosterone deficiency. Because testosterone exhibits diurnal variation with peak concentrations in the early morning, the diagnosis should rest on at least two separate fasting morning measurements that are consistently below the threshold (commonly cited near 300 ng/dL for total testosterone), not on a single, non-morning value. This patient's single afternoon value of 280 ng/dL is insufficient on its own. Confirming the biochemical diagnosis is especially important here given his cardiovascular history before committing to therapy.
Option A: Option A is incorrect; a single afternoon testosterone value is not adequate to diagnose hypogonadism — repeat morning testing is required.
Option B: Option B is incorrect; symptoms alone, without biochemical confirmation, do not establish the diagnosis; testosterone deficiency must be demonstrated.
Option C: Option C is incorrect; estradiol is not the confirmatory test for male hypogonadism; morning total (and as needed free) testosterone is the diagnostic measure.
Option D: Option D is incorrect; while prolactin is part of the evaluation of low testosterone (to assess for a prolactinoma), a normal prolactin does not substitute for confirming low testosterone on repeat morning measurement before starting therapy.
6. [CASE 2 — QUESTION 6]
Continuing with the same patient. His diagnosis of hypogonadism is confirmed with repeat morning measurements. Given his cardiovascular history and a baseline hematocrit at the upper end of normal (49%), his physician wants to minimize the risk of erythrocytosis. Which testosterone formulation strategy best addresses this concern?
A) Biweekly intramuscular testosterone enanthate, because the supraphysiological peaks it produces are protective against erythrocytosis.
B) Testosterone undecanoate 1,000 mg intramuscular every 10 weeks, because larger, less frequent doses minimize erythrocytosis.
C) A transdermal testosterone preparation (gel or patch), because transdermal delivery produces lower, steadier serum testosterone levels and is associated with less erythrocytosis than injectable esters, which generate supraphysiological peaks that drive greater red cell mass expansion.
D) High-dose oral methyltestosterone, because oral androgens do not affect hematocrit.
E) Subcutaneous testosterone pellets at the maximum dose, because pellet implantation eliminates any risk of erythrocytosis.
ANSWER: C
Rationale:
Option C is correct. Erythrocytosis is the most common dose-dependent adverse effect of testosterone replacement therapy and is more pronounced with injectable esters, which produce supraphysiological peak testosterone concentrations that strongly stimulate erythropoiesis. Transdermal preparations (gels and patches) deliver lower, steadier serum testosterone levels and are associated with less erythrocytosis, making them the preferable choice in a man with an already high-normal baseline hematocrit and significant cardiovascular risk.
Option A: Option A is incorrect; the supraphysiological peaks of biweekly injectable esters drive greater (not less) erythrocytosis, so this is the opposite of protective.
Option B: Option B is incorrect; testosterone undecanoate is still an injectable that can cause erythrocytosis, and larger doses do not minimize this risk; it also requires the 30-minute observation for pulmonary oil microembolism.
Option D: Option D is incorrect; oral methyltestosterone is hepatotoxic (17-alpha-alkylated) and is not a safe choice, and oral androgens do affect hematocrit; this option is incorrect on multiple grounds.
Option E: Option E is incorrect; subcutaneous pellets do not eliminate erythrocytosis risk and cannot be dose-adjusted once implanted, which is a disadvantage in a patient whose hematocrit may rise.
7. [CASE 2 — QUESTION 7]
Continuing with the same patient. Despite starting on a transdermal gel, at his 6-month follow-up his hematocrit has risen to 56%, and he reports new mild headaches. Which of the following is the most appropriate management of his erythrocytosis?
A) Continue the current dose unchanged and recheck in another year, since a hematocrit of 56% is within an acceptable range for men on testosterone therapy.
B) Reduce the testosterone dose and consider therapeutic phlebotomy, because the hematocrit now exceeds the 54% action threshold at which the increased blood viscosity raises thrombotic risk; reassessment of the testosterone regimen is warranted, particularly given his cardiovascular history.
C) Increase the testosterone dose, since higher testosterone will suppress erythropoiesis and lower the hematocrit.
D) Add an iron supplement to support the elevated red cell mass and continue the current testosterone dose without other changes.
E) Permanently stop testosterone and refuse any future androgen therapy, as a hematocrit of 56% represents an irreversible contraindication to all future treatment.
ANSWER: B
Rationale:
Option B is correct. A hematocrit above 54% is the established threshold for intervention in men on testosterone replacement therapy because elevated red cell mass increases whole-blood viscosity and raises the risk of venous and arterial thrombotic events. This patient's hematocrit of 56% with new headaches (a hyperviscosity symptom) and a significant cardiovascular history warrants action: reduce the testosterone dose and consider therapeutic phlebotomy (further formulation adjustment can also be considered).
Option A: Option A is incorrect; a hematocrit of 56% exceeds the 54% threshold and requires intervention, not another year of observation.
Option C: Option C is incorrect; increasing the testosterone dose would worsen erythrocytosis, since testosterone stimulates erythropoiesis.
Option D: Option D is incorrect; adding iron would support further erythropoiesis and is counterproductive; the goal is to reduce red cell mass, not facilitate its expansion.
Option E: Option E is incorrect; erythrocytosis is a manageable, dose-related effect; it is not an irreversible contraindication to all future androgen therapy, and treatment can typically continue after appropriate dose reduction and phlebotomy.
8. [CASE 2 — QUESTION 8]
Continuing with the same patient. After dose adjustment, he remains on testosterone therapy. Several months later he presents with new palpitations and is found to be in atrial fibrillation; he also reports recent pleuritic chest pain, and a CT pulmonary angiogram confirms a segmental pulmonary embolism. He has no other clear provoking factors. Which of the following best reflects the relationship between testosterone therapy and these specific events?
A) These events confirm that testosterone therapy substantially increases the rate of major adverse cardiovascular events (myocardial infarction, stroke, and cardiovascular death), which is the expected effect demonstrated in large randomized trials.
B) Testosterone therapy reduces the risk of both atrial fibrillation and venous thromboembolism, so these events must be entirely unrelated to his therapy.
C) Atrial fibrillation and pulmonary embolism have no recognized association with testosterone therapy, so testosterone can be confidently excluded as a contributor.
D) Although large randomized data indicate testosterone therapy is non-inferior to placebo for the composite of major adverse cardiovascular events in men with elevated cardiovascular risk, the same data identified increased rates of atrial fibrillation and pulmonary embolism with testosterone; his new atrial fibrillation and pulmonary embolism are consistent with these recognized risks and warrant treatment of the arrhythmia and thromboembolism and reassessment of continued therapy.
E) These events prove that testosterone therapy is absolutely contraindicated in every man regardless of individual risk, and no man should receive testosterone replacement.
ANSWER: D
Rationale:
Option D is correct. Contemporary randomized evidence in hypogonadal men with elevated cardiovascular risk showed that testosterone replacement therapy was non-inferior to placebo for the primary composite of major adverse cardiovascular events (non-fatal myocardial infarction, non-fatal stroke, cardiovascular death). However, the same evidence identified increased rates of specific secondary events — notably atrial fibrillation and pulmonary embolism (and acute kidney injury). This patient's new atrial fibrillation and confirmed pulmonary embolism, without other provoking factors, are consistent with these recognized associations; management includes treating the arrhythmia and the thromboembolism and reassessing whether to continue testosterone.
Option A: Option A is incorrect; the major adverse cardiovascular event composite was non-inferior, not substantially increased, so these events do not confirm an increase in that composite endpoint.
Option B: Option B is incorrect; testosterone therapy does not reduce atrial fibrillation or venous thromboembolism risk — the evidence shows increased rates.
Option C: Option C is incorrect; atrial fibrillation and pulmonary embolism are recognized associations with testosterone therapy, so it cannot be excluded as a contributor.
Option E: Option E is incorrect; the evidence does not render testosterone absolutely contraindicated for all men; it informs individualized risk-benefit assessment and monitoring, with specific contraindications rather than a universal prohibition.
9. [CASE 3 — QUESTION 9]
A 64-year-old man presents with bothersome lower urinary tract symptoms — weak stream, hesitancy, and nocturia — and is found on examination to have a moderately enlarged, benign-feeling prostate. His physician prescribes finasteride 5 mg daily for benign prostatic hyperplasia (BPH). Which of the following best describes the mechanism by which finasteride reduces prostate volume and improves his symptoms?
A) Finasteride is a competitive inhibitor of type 2 5 alpha-reductase that reduces conversion of testosterone to dihydrotestosterone (DHT) in the prostate; lowering intraprostatic DHT (by over 90%) reduces prostatic epithelial and stromal proliferation, producing a sustained reduction in prostate volume over 6 to 12 months that relieves obstructive symptoms.
B) Finasteride is an androgen receptor antagonist that competitively blocks testosterone and DHT binding in the prostate, producing immediate prostate shrinkage within days.
C) Finasteride is an alpha-1 adrenergic receptor antagonist that relaxes prostatic smooth muscle, improving urinary flow without changing prostate size.
D) Finasteride inhibits aromatase, lowering estradiol and thereby shrinking the prostate.
E) Finasteride suppresses pituitary LH secretion, lowering serum testosterone to castrate levels and shrinking the prostate through global androgen deprivation.
ANSWER: A
Rationale:
Option A is correct. Finasteride is a competitive inhibitor of type 2 5 alpha-reductase, the isoform predominant in the prostate, and reduces conversion of testosterone to dihydrotestosterone (DHT) — the primary androgen driving prostatic growth. At 5 mg daily it lowers intraprostatic DHT by over 90% (and serum DHT by ~70%), producing a sustained reduction in prostate volume of approximately 20% to 30% over 6 to 12 months, which relieves obstructive lower urinary tract symptoms and reduces the risk of acute urinary retention and the need for surgery over time.
Option B: Option B is incorrect; finasteride is not an androgen receptor antagonist, and its effect is not immediate — prostate volume reduction develops gradually over months, not days.
Option C: Option C is incorrect; finasteride is not an alpha-1 blocker; alpha-1 antagonists (e.g., tamsulosin) relax prostatic smooth muscle for rapid symptom relief without changing prostate size, which is a different drug class.
Option D: Option D is incorrect; finasteride does not inhibit aromatase or work by lowering estradiol.
Option E: Option E is incorrect; finasteride does not suppress pituitary LH or lower serum testosterone to castrate levels; it acts locally by reducing DHT production while leaving testosterone largely intact.
10. [CASE 3 — QUESTION 10]
Continuing with the same patient. After 6 months on finasteride, his prostate-specific antigen (PSA) is measured at 1.5 ng/mL. His physician wants to interpret this value correctly in the context of finasteride therapy. Which of the following is the most appropriate interpretation?
A) The measured PSA of 1.5 ng/mL should be used directly without adjustment, since finasteride has no effect on PSA levels.
B) The measured PSA should be halved to approximately 0.75 ng/mL to estimate the true value, since finasteride artificially elevates PSA.
C) Finasteride makes PSA completely uninterpretable, so the value should be disregarded entirely.
D) The measured PSA should be multiplied by ten, since finasteride suppresses PSA by approximately 90%.
E) Because finasteride reduces PSA by approximately 50% after about 6 months of therapy, the measured value should be doubled — to approximately 3.0 ng/mL — to estimate the equivalent untreated PSA; failure to apply this correction risks missing a clinically significant PSA elevation.
ANSWER: E
Rationale:
Option E is correct. Finasteride reduces serum PSA by approximately 50% after about 6 months of therapy by suppressing DHT-driven PSA transcription in prostatic epithelium. To interpret a PSA value in a man on finasteride, the measured value should be doubled to estimate the equivalent untreated PSA — here, 1.5 ng/mL corresponds to approximately 3.0 ng/mL. Failing to apply this correction risks underestimating the true PSA and missing a clinically significant elevation that would warrant further evaluation for prostate cancer.
Option A: Option A is incorrect; finasteride does reduce PSA (by ~50%), so using the measured value without adjustment underestimates the true value.
Option B: Option B is incorrect; finasteride lowers rather than raises PSA, so halving the measured value moves in the wrong direction.
Option C: Option C is incorrect; PSA remains interpretable in men on finasteride when the doubling correction is applied; it should not be disregarded.
Option D: Option D is incorrect; finasteride reduces PSA by approximately 50% (not 90%), so the correct correction is to double the value, not multiply by ten.
11. [CASE 3 — QUESTION 11]
Continuing with the same patient. He remains adherent to finasteride. Over the following 9 months, his PSA rises steadily from 1.5 to 2.8 ng/mL while he continues the medication. His digital rectal examination remains benign. Which of the following is the most appropriate interpretation and action?
A) The rise is expected and benign because the prostate continues to grow with age; no further evaluation is needed as long as the value stays under 4 ng/mL.
B) The finasteride has lost effectiveness; the appropriate action is to increase the dose to re-suppress the PSA and continue routine screening.
C) A sustained rise in PSA during continued, adherent finasteride therapy is abnormal and concerning for prostate cancer — because ongoing DHT suppression should keep PSA low — and warrants urologic evaluation regardless of the absolute value.
D) The rising PSA reflects finasteride-induced prostatic inflammation and requires no oncologic evaluation.
E) PSA should no longer be monitored in this patient because finasteride renders it permanently uninterpretable.
ANSWER: C
Rationale:
Option C is correct. Once finasteride has produced its expected ~50% PSA reduction and the value has stabilized, the drug's ongoing DHT suppression should keep PSA low. Therefore, a sustained upward trend in PSA during continued, adherent finasteride therapy is abnormal and is a recognized warning sign for prostate cancer. This patient's PSA has nearly doubled over 9 months on stable therapy, which warrants urologic evaluation regardless of whether the absolute value remains below a nominal threshold such as 4 ng/mL. (Applying the doubling correction, 2.8 ng/mL corresponds to ~5.6 ng/mL untreated, further supporting evaluation.)
Option A: Option A is incorrect; a rising PSA on stable finasteride is not benign age-related growth, and reassurance based solely on staying under 4 ng/mL ignores the suppressive pharmacodynamics that should keep the value low.
Option B: Option B is incorrect; finasteride does not "lose effectiveness" in an adherent patient, and increasing the dose to mask a rising PSA could dangerously delay a cancer diagnosis.
Option D: Option D is incorrect; the rise is not explained by drug-induced inflammation, and forgoing oncologic evaluation would be unsafe.
Option E: Option E is incorrect; PSA remains interpretable and valuable on finasteride when correction and trend principles are applied; monitoring should continue.
12. [CASE 3 — QUESTION 12]
Continuing with the same patient. His urologic evaluation is reassuring, and he continues finasteride. At a follow-up visit he mentions that his adult daughter, who is pregnant, lives with him and sometimes helps organize his medications. Which of the following counseling points is most important?
A) There is no concern, because finasteride tablets pose a risk to a pregnant woman only if she swallows several of them at once.
B) His pregnant daughter must not handle crushed or broken finasteride tablets, because finasteride can reduce DHT required for normal development of a male fetus's external genitalia; intact coated tablets limit dermal absorption, but broken or crushed tablets pose a fetal exposure risk and should not be handled by a woman who is or may become pregnant.
C) The pregnant daughter should stop taking her prenatal vitamins while handling his finasteride because of a drug interaction.
D) Finasteride is hazardous to a female fetus, not a male fetus, so the concern applies only if the fetus is known to be female.
E) Finasteride exposure is dangerous only in the third trimester, so handling the tablets during early pregnancy carries no risk.
ANSWER: B
Rationale:
Option B is correct. 5 alpha-reductase inhibitors are contraindicated in pregnancy because DHT is required for normal virilization of the male fetal external genitalia; fetal exposure can impair this development. A relevant exposure route for a pregnant household member is dermal absorption from handling crushed or broken tablets. Intact, coated finasteride tablets limit dermal absorption, but broken or crushed tablets should not be handled by a woman who is or may become pregnant. The pregnant daughter should therefore avoid handling broken or crushed tablets.
Option A: Option A is incorrect; the risk is not limited to ingesting multiple tablets — dermal absorption from handling crushed or broken tablets is the specific concern.
Option C: Option C is incorrect; there is no interaction requiring her to stop prenatal vitamins, and stopping them would be harmful; the genuine concern is fetal DHT reduction from handling broken tablets.
Option D: Option D is incorrect; the teratogenic risk is to a male fetus (impaired external genital virilization), not a female fetus.
Option E: Option E is incorrect; male external genital development occurs in the first trimester, so early-pregnancy exposure is the period of greatest concern, not the third trimester.
13. [CASE 4 — QUESTION 13]
A 71-year-old man is diagnosed with metastatic prostate cancer involving the lumbar spine and is scheduled to begin androgen deprivation therapy with the GnRH agonist leuprolide. He has intermittent low back pain but no neurologic deficits. His oncologist plans to start a non-steroidal androgen receptor antagonist a few days before the leuprolide injection. Which of the following best explains the rationale for this co-administration?
A) The androgen receptor antagonist accelerates pituitary downregulation, shortening the time for leuprolide to achieve castrate testosterone, and provides no independent receptor-level protection.
B) The androgen receptor antagonist is given to treat the patient's pre-existing back pain through a direct analgesic effect unrelated to testosterone.
C) GnRH agonists cause an initial profound drop in testosterone followed by a late rebound surge after several months; the antagonist blocks this late rebound rather than any early effect.
D) GnRH agonists initially stimulate the pituitary, producing a transient surge in LH and testosterone (the "flare") during the first one to two weeks before receptor downregulation produces sustained suppression; in a man with spinal metastases, this testosterone surge could stimulate tumor growth and precipitate spinal cord compression, so a non-steroidal androgen receptor antagonist (e.g., bicalutamide) is given before and during the flare to block the androgen receptor and protect against its consequences until castrate testosterone is achieved.
E) GnRH agonists immediately and permanently suppress testosterone with no initial surge, so the antagonist is purely precautionary and has no pharmacologic rationale.
ANSWER: D
Rationale:
Option D is correct. GnRH agonists such as leuprolide initially stimulate pituitary GnRH receptors, producing a transient surge in LH and testosterone — the "flare" — during the first one to two weeks before receptor downregulation produces sustained castrate testosterone. In a man with spinal (vertebral) metastases, this testosterone surge can transiently stimulate tumor growth and precipitate serious complications such as spinal cord compression. Co-administering a non-steroidal androgen receptor antagonist (e.g., bicalutamide) beginning before and continuing through the flare period blocks the androgen receptor in tumor tissue, protecting against the consequences of the surge until castrate testosterone is reached.
Option A: Option A is incorrect; the antagonist does not accelerate pituitary downregulation; it provides independent receptor-level blockade during the flare.
Option B: Option B is incorrect; the antagonist's role is flare protection through androgen receptor blockade, not direct analgesia.
Option C: Option C is incorrect; the clinically important surge is the early flare (first one to two weeks), not a late rebound after months.
Option E: Option E is incorrect; GnRH agonists do produce an initial testosterone surge, so the co-administration has a clear pharmacologic rationale (flare protection), not merely precaution.
14. [CASE 4 — QUESTION 14]
Continuing with the same patient. After the flare period, the leuprolide is continued, and the oncologist discusses maintaining the bicalutamide alongside it to achieve combined androgen blockade. The patient asks why both drugs are used together rather than the androgen receptor antagonist alone. Which of the following best explains the rationale for combined androgen blockade?
A) Bicalutamide monotherapy does not suppress gonadotropin secretion (it lacks progestogenic activity) and, by blocking the androgen receptor at the hypothalamus and pituitary, removes testosterone negative feedback, raising LH and driving testicular testosterone approximately 1.5-fold above baseline; this elevated testosterone competes with bicalutamide at the receptor. Adding a GnRH agonist suppresses testicular testosterone production, eliminating this escape and achieving more complete androgen blockade.
B) Bicalutamide monotherapy fully suppresses testicular testosterone to castrate levels by itself, so the GnRH agonist is redundant and added only out of caution.
C) The GnRH agonist and bicalutamide both act at the androgen receptor, and combining two receptor antagonists doubles the receptor blockade through an additive binding effect.
D) Bicalutamide stimulates adrenal androgen production, and the GnRH agonist is added specifically to suppress the adrenal gland.
E) The combination is used because bicalutamide alone is rapidly inactivated by hepatic metabolism, and the GnRH agonist inhibits this metabolism to prolong bicalutamide's effect.
ANSWER: A
Rationale:
Option A is correct. Bicalutamide is a non-steroidal androgen receptor antagonist without progestogenic activity, so it does not suppress gonadotropin secretion. By blocking the androgen receptor at the hypothalamus and pituitary, it removes testosterone's negative feedback, raising LH and driving testicular testosterone to approximately 1.5 times baseline. This elevated circulating testosterone competes with bicalutamide for receptor binding in tumor tissue, limiting the completeness of blockade. Adding a GnRH agonist (or antagonist) suppresses testicular testosterone production, eliminating this testosterone escape and achieving combined androgen blockade with more complete androgen suppression.
Option B: Option B is incorrect; bicalutamide monotherapy does not suppress testicular testosterone to castrate levels — it actually raises testosterone — so the GnRH agonist is not redundant.
Option C: Option C is incorrect; the GnRH agonist does not act at the androgen receptor; it suppresses testicular testosterone production via pituitary downregulation, a different mechanism from receptor blockade.
Option D: Option D is incorrect; bicalutamide does not stimulate adrenal androgen production, and the GnRH agonist suppresses testicular (not adrenal) testosterone.
Option E: Option E is incorrect; the rationale is not a pharmacokinetic interaction prolonging bicalutamide's effect; it is the elimination of testosterone escape by suppressing testicular testosterone.
15. [CASE 4 — QUESTION 15]
Continuing with the same patient. After a period of disease control, his prostate cancer progresses biochemically despite castrate testosterone levels (castration-resistant disease). His oncologist switches him to enzalutamide. Which of the following best describes how enzalutamide differs pharmacologically from bicalutamide?
A) Enzalutamide suppresses gonadotropin secretion through progestogenic activity, unlike bicalutamide, which is why it is effective in castration-resistant disease.
B) Enzalutamide is a second-generation non-steroidal androgen receptor antagonist that binds the receptor with approximately 5 to 8 times greater affinity than bicalutamide and additionally inhibits nuclear translocation of the androgen receptor-ligand complex and androgen receptor binding to DNA, producing more complete pathway blockade; it also carries a distinctive CNS profile including a seizure risk not characteristic of bicalutamide.
C) Enzalutamide is a 5 alpha-reductase inhibitor that lowers DHT, which is its primary advantage over bicalutamide in castration-resistant disease.
D) Enzalutamide and bicalutamide are pharmacologically identical, differing only in dosing frequency.
E) Enzalutamide acts by lowering androgen synthesis through CYP17A1 inhibition, identical to abiraterone.
ANSWER: B
Rationale:
Option B is correct. Enzalutamide is a second-generation non-steroidal androgen receptor (AR) antagonist developed to overcome resistance to first-generation agents such as bicalutamide. It binds the AR with approximately 5 to 8 times greater affinity than bicalutamide and, beyond competitive binding, also inhibits nuclear translocation of the AR-ligand complex and impairs AR binding to DNA and coactivator recruitment, producing more complete AR pathway blockade — properties that underlie its activity in castration-resistant disease. It also has a distinctive CNS adverse effect profile, including fatigue, cognitive impairment, and a seizure risk (related to GABA-A negative allosteric modulation) not characteristic of bicalutamide.
Option A: Option A is incorrect; enzalutamide does not suppress gonadotropins through progestogenic activity; it is an AR antagonist, and its efficacy derives from more complete AR pathway blockade.
Option C: Option C is incorrect; enzalutamide is not a 5 alpha-reductase inhibitor; it acts at the androgen receptor, not by lowering DHT synthesis.
Option D: Option D is incorrect; enzalutamide and bicalutamide are not pharmacologically identical — enzalutamide has higher affinity and additional mechanisms (blocking translocation and DNA binding) and a different adverse effect profile.
Option E: Option E is incorrect; enzalutamide does not inhibit CYP17A1; lowering androgen synthesis via CYP17A1 inhibition is the mechanism of abiraterone, a different agent.
16. [CASE 4 — QUESTION 16]
Continuing with the same patient. After initial benefit, his disease progresses on enzalutamide. Circulating tumor cell testing returns positive for AR-V7. Which of the following is the most appropriate next treatment, and why?
A) Switch to apalutamide, which retains full activity against AR-V7-positive disease because it binds the ligand-binding domain more tightly than enzalutamide.
B) Switch to abiraterone alone, since lowering androgen synthesis effectively controls a ligand-independent AR-V7-driven tumor.
C) Add exogenous testosterone to overwhelm the variant receptor and restore hormone sensitivity.
D) Discontinue all systemic therapy and proceed directly to hospice, as no therapy retains activity once AR-V7 is present.
E) Initiate taxane chemotherapy (docetaxel or cabazitaxel), because AR-V7 is a constitutively active androgen receptor splice variant lacking the ligand-binding domain that confers resistance to androgen receptor-directed agents, whereas taxanes act on microtubules independently of androgen receptor status and retain activity.
ANSWER: E
Rationale:
Option E is correct. AR-V7 is a constitutively active, truncated androgen receptor splice variant that lacks the C-terminal ligand-binding domain (LBD); it signals without androgen and cannot be blocked by competitive AR antagonists (enzalutamide, apalutamide, darolutamide, bicalutamide), all of which bind the LBD, nor is it effectively controlled by abiraterone, which lowers androgen synthesis (a receptor that does not need ligand is not suppressed by ligand depletion). Taxane chemotherapy (docetaxel or cabazitaxel) acts on microtubules to disrupt mitotic and intracellular trafficking — a mechanism independent of the androgen receptor and its splice variants — and therefore retains activity in AR-V7-positive disease, making it the appropriate next therapy.
Option A: Option A is incorrect; apalutamide also binds the LBD and cannot block a receptor that lacks the LBD; it does not retain activity against AR-V7-positive disease.
Option B: Option B is incorrect; abiraterone depletes androgen, which does not meaningfully suppress a ligand-independent, constitutively active receptor.
Option C: Option C is incorrect; adding testosterone to metastatic prostate cancer would stimulate androgen-responsive disease and is not a rational therapy here.
Option D: Option D is incorrect; AR-V7 positivity predicts resistance to AR-directed agents but not to taxanes, so effective systemic therapy remains available and proceeding directly to hospice is inappropriate.
17. [CASE 5 — QUESTION 17]
A 26-year-old woman with polycystic ovary syndrome (PCOS) presents with hirsutism and acne that have not responded adequately to combined oral contraceptives. Her physician adds spironolactone 100 mg daily, planning to titrate upward. Which of the following best describes the mechanisms by which spironolactone improves her hirsutism at anti-androgenic doses?
A) Spironolactone improves hirsutism solely by acting as a diuretic, reducing fluid retention in hair follicles.
B) Spironolactone acts as an androgen receptor agonist that downregulates follicular androgen receptors through chronic overstimulation.
C) Spironolactone, at the doses used for hirsutism (typically 100 to 200 mg daily), produces anti-androgenic effects through competitive androgen receptor blockade and inhibition of CYP17A1 (17-hydroxylase/17,20-lyase) at higher doses, which reduces adrenal androgen synthesis, with possible additional enhancement of testosterone metabolic clearance.
D) Spironolactone stimulates aromatase, increasing conversion of androgens to estrogens, which is its sole anti-androgenic mechanism.
E) Spironolactone suppresses pituitary LH to castrate levels, eliminating all ovarian and adrenal androgen production.
ANSWER: C
Rationale:
Option C is correct. At the doses used for hirsutism and other anti-androgenic indications (typically 100 to 200 mg daily), spironolactone produces its anti-androgenic effect through competitive androgen receptor blockade (spironolactone and its active metabolite canrenone displace testosterone and DHT from the receptor) and inhibition of CYP17A1 (the 17-hydroxylase/17,20-lyase enzyme) at higher doses, which reduces adrenal androgen synthesis; it may also enhance metabolic clearance of testosterone. These mechanisms together reduce androgenic stimulation of the hair follicle, improving hirsutism.
Option A: Option A is incorrect; spironolactone's benefit in hirsutism is anti-androgenic, not a result of diuretic fluid reduction in follicles.
Option B: Option B is incorrect; spironolactone is an androgen receptor antagonist, not an agonist; it blocks rather than stimulates the receptor.
Option D: Option D is incorrect; spironolactone does not stimulate aromatase, and aromatase stimulation is not its mechanism.
Option E: Option E is incorrect; spironolactone does not suppress pituitary LH to castrate levels; its anti-androgenic action is via receptor blockade and steroidogenic enzyme inhibition, not global gonadotropin suppression.
18. [CASE 5 — QUESTION 18]
Continuing with the same patient. She returns having been started on lisinopril for newly diagnosed hypertension by another provider, and she has also begun using a potassium-based salt substitute. She now reports fatigue and palpitations. Which of the following is the most important safety concern in this medication combination?
A) The combination markedly increases the risk of hyperkalemia, because spironolactone (a mineralocorticoid receptor antagonist that reduces renal potassium excretion), the ACE inhibitor lisinopril (which lowers aldosterone and further reduces potassium excretion), and the potassium-based salt substitute (an exogenous potassium load) exert additive potassium-raising effects; serum potassium should be checked and the salt substitute discontinued.
B) The combination causes profound hypokalemia, requiring aggressive potassium supplementation.
C) The combination produces hypernatremia from the salt substitute, requiring sodium restriction as the priority.
D) The combination causes hypocalcemia through spironolactone's effect on calcium handling.
E) The combination has no clinically important interaction and requires no monitoring.
ANSWER: A
Rationale:
Option A is correct. Spironolactone is a mineralocorticoid receptor antagonist that reduces renal potassium excretion, predisposing to hyperkalemia. In this patient, three potassium-raising influences are additive: spironolactone, the ACE inhibitor lisinopril (which lowers aldosterone and thereby further reduces potassium excretion), and a potassium-based salt substitute (an exogenous potassium load). Her fatigue and palpitations are concerning for hyperkalemia. The appropriate response is to check serum potassium and discontinue the potassium-based salt substitute, with close monitoring of the overall regimen.
Option B: Option B is incorrect; spironolactone is potassium-sparing and causes hyperkalemia, not hypokalemia, so potassium supplementation would be dangerous.
Option C: Option C is incorrect; a potassium-based salt substitute raises potassium, not sodium; hypernatremia is not the concern.
Option D: Option D is incorrect; spironolactone does not characteristically cause hypocalcemia.
Option E: Option E is incorrect; this combination has a clinically important, potentially dangerous interaction (additive hyperkalemia risk) that clearly requires monitoring.
19. [CASE 5 — QUESTION 19]
Continuing with the same patient. Her potassium issue is resolved by stopping the salt substitute, and her hirsutism improves on spironolactone. At a follow-up visit she mentions she has stopped using contraception because she and her partner are considering starting a family. Which of the following is the most important counseling point regarding spironolactone?
A) Spironolactone is completely safe in pregnancy and may be continued without concern while attempting conception.
B) Spironolactone should be stopped only after a positive pregnancy test, as there is no risk during the periconceptional period.
C) Spironolactone is teratogenic only to a female fetus, so it may be continued if the fetus is known to be female.
D) Spironolactone is potentially teratogenic to a male fetus because of its anti-androgenic activity (animal data demonstrate feminization of male offspring), so reliable contraception is required for women of childbearing potential, and the drug should be reconsidered or discontinued in a woman who is attempting to conceive.
E) Spironolactone enhances male fetal virilization and is therefore beneficial during pregnancy.
ANSWER: D
Rationale:
Option D is correct. Spironolactone's anti-androgenic activity (androgen receptor blockade and reduced androgen synthesis) makes it potentially teratogenic to a male fetus; animal studies demonstrate feminization of male offspring. For this reason, reliable contraception is required for women of childbearing potential taking spironolactone, and in a woman who is attempting to conceive, the drug should be reconsidered or discontinued and an alternative approach to her hirsutism considered.
Option A: Option A is incorrect; spironolactone is not safe to continue without concern while attempting conception, given its potential to feminize a male fetus.
Option B: Option B is incorrect; the risk is present during the periconceptional and early pregnancy period (when male external genital development occurs), so waiting for a positive pregnancy test before stopping is inappropriate.
Option C: Option C is incorrect; the teratogenic concern is for a male fetus (feminization), not a female fetus, and fetal sex is not known at conception, so this reasoning is unsafe.
Option E: Option E is incorrect; spironolactone does not enhance male fetal virilization — it opposes androgen action and can impair it — and it is not beneficial during pregnancy.
20. [CASE 5 — QUESTION 20]
Continuing with the same patient. She decides to defer conception and asks about other anti-androgen options for her hirsutism, having read about several agents online. Which of the following correctly pairs an alternative anti-androgen with its characteristic serious adverse effect?
A) Finasteride is associated with a dose-dependent risk of meningioma, which is its principal serious adverse effect in this setting.
B) Bicalutamide, a non-steroidal androgen receptor antagonist sometimes used off-label for hirsutism, carries a characteristic risk of hepatotoxicity (requiring liver function monitoring), whereas cyproterone acetate, a steroidal anti-androgen and progestin used for hirsutism in some countries, carries a dose- and duration-dependent risk of meningioma and venous thromboembolism.
C) Cyproterone acetate is free of serious adverse effects and is preferred specifically because it has no thromboembolic or neoplastic risk.
D) Bicalutamide characteristically causes hyperkalemia identical to spironolactone, which is its principal serious risk.
E) Finasteride and bicalutamide both characteristically cause meningioma, which distinguishes them from spironolactone.
ANSWER: B
Rationale:
Option B is correct. Among alternative anti-androgens, the characteristic serious adverse effects discriminate the agents. Bicalutamide, a non-steroidal androgen receptor antagonist sometimes used off-label for hirsutism, carries a characteristic risk of hepatotoxicity and requires liver function monitoring. Cyproterone acetate, a steroidal anti-androgen and progestin used for hirsutism in some countries (not approved in the United States), carries a dose- and duration-dependent risk of meningioma (linked to its progestogenic activity) as well as venous thromboembolism.
Option A: Option A is incorrect; finasteride is not associated with meningioma; meningioma is a cyproterone acetate-associated risk.
Option C: Option C is incorrect; cyproterone acetate is not free of serious adverse effects — it carries meningioma and thromboembolic risks.
Option D: Option D is incorrect; bicalutamide does not characteristically cause hyperkalemia (that is spironolactone's mineralocorticoid effect); bicalutamide's characteristic serious risk is hepatotoxicity.
Option E: Option E is incorrect; finasteride and bicalutamide are not characteristically associated with meningioma; meningioma is specifically linked to cyproterone acetate.
21. [CASE 6 — QUESTION 21]
A 29-year-old male amateur bodybuilder is brought to clinic by his partner because of yellowing of his eyes and skin, itching, and right upper quadrant discomfort. He eventually discloses an 8-month self-administered regimen that includes oral stanozolol and oral oxymetholone, along with injectable testosterone esters. Laboratory testing shows a cholestatic pattern with markedly elevated bilirubin. Which of the following best explains the hepatic injury in this patient?
A) The injectable testosterone esters are the cause of his cholestatic hepatotoxicity, because 17-beta-esterified steroids are highly hepatotoxic.
B) His liver injury is unrelated to anabolic steroids and is most likely autoimmune hepatitis.
C) Aromatization of the anabolic steroids to estrogenic metabolites is the cause of the cholestasis, treatable only with an aromatase inhibitor.
D) The hepatotoxicity is due to erythrocytosis-induced hepatic congestion from elevated red cell mass.
E) The oral C17-alpha-alkylated anabolic steroids (stanozolol and oxymetholone) are responsible; the 17-alpha-alkyl group, which confers oral bioavailability by blocking first-pass hepatic oxidation, also impairs hepatic conjugation and biliary excretion, producing intrahepatic cholestasis (and, with prolonged use, peliosis hepatis and hepatic tumors), whereas the injectable 17-beta-esterified testosterone does not carry this hepatotoxicity.
ANSWER: E
Rationale:
Option E is correct. Stanozolol and oxymetholone are oral C17-alpha-alkylated anabolic-androgenic steroids. The 17-alpha-alkyl group confers oral bioavailability by blocking first-pass hepatic oxidation at the 17-beta hydroxyl, but it also impairs the hepatocyte's normal conjugation and biliary excretion of the steroid, producing dose-dependent intrahepatic cholestasis and, with prolonged high-dose use, peliosis hepatis and hepatocellular tumors. This patient's cholestatic pattern with markedly elevated bilirubin and jaundice in the setting of oral 17-alpha-alkylated steroid use is characteristic. In contrast, the injectable 17-beta-esterified testosterone he is also using does not carry this hepatotoxicity, because after ester cleavage the steroid undergoes normal hepatic metabolism.
Option A: Option A is incorrect; injectable 17-beta-esterified testosterone esters are not the cause — they are not hepatotoxic in this way; the oral 17-alpha-alkylated agents are responsible.
Option B: Option B is incorrect; while autoimmune hepatitis is in the broad differential of liver injury, the cholestatic pattern in a man using oral 17-alpha-alkylated steroids points to drug-induced cholestasis.
Option C: Option C is incorrect; the hepatotoxicity arises from impaired conjugation and biliary excretion due to 17-alpha-alkylation, not from aromatization to estrogenic metabolites; an aromatase inhibitor does not treat it.
Option D: Option D is incorrect; erythrocytosis does not cause cholestatic hepatic injury through hepatic congestion; the cholestatic pattern reflects the 17-alpha-alkylated steroid effect.
22. [CASE 6 — QUESTION 22]
Continuing with the same patient. After his liver injury is addressed and he is counseled to stop oral agents, a cardiac evaluation prompted by exertional dyspnea reveals concentric left ventricular hypertrophy with impaired diastolic function, a markedly reduced HDL cholesterol, and premature coronary calcification on imaging. Which of the following best characterizes the cardiovascular consequences of long-term anabolic-androgenic steroid (AAS) use?
A) These findings represent normal physiological athletic remodeling (eccentric hypertrophy with enhanced diastolic function) and carry no increased cardiovascular risk.
B) The reduced HDL cholesterol is cardioprotective, and the concentric hypertrophy reverses completely within days of stopping AAS, so his cardiovascular risk is minimal.
C) Long-term AAS use produces pathological concentric left ventricular hypertrophy with impaired diastolic compliance and arrhythmia predisposition, an atherogenic lipid profile (notably markedly reduced HDL cholesterol with variable LDL elevation), and accelerated premature coronary artery disease; together these substantially increase the risk of malignant arrhythmia, sudden cardiac death, and coronary events, making cardiovascular toxicity the leading cause of AAS-related premature mortality.
D) The coronary calcification is simply age-appropriate atherosclerosis unrelated to AAS, and the lipid changes are independent of his steroid use.
E) The cardiac findings are entirely explained by erythrocytosis and resolve fully with phlebotomy alone, with no structural or atherosclerotic component.
ANSWER: C
Rationale:
Option C is correct. Cardiovascular toxicity is the leading cause of premature mortality in long-term anabolic-androgenic steroid (AAS) users, and this patient exhibits its hallmark features. AAS drive pathological concentric left ventricular hypertrophy (increased wall thickness with reduced or normal chamber volume) with impaired diastolic compliance and arrhythmia predisposition — distinct from the eccentric, function-preserving remodeling of athletic training. AAS also produce an atherogenic lipid profile, most characteristically a marked reduction in HDL cholesterol with variable LDL elevation, and accelerate coronary atherosclerosis (premature coronary calcification in a young man). Together these substantially raise the risk of malignant arrhythmia, sudden cardiac death, and coronary events.
Option A: Option A is incorrect; concentric hypertrophy with impaired diastolic function is pathological, not the eccentric, function-preserving remodeling of athletic training, and it carries real risk.
Option B: Option B is incorrect; low HDL is atherogenic (not protective), and AAS-associated structural changes and fibrosis are not reliably reversible within days; his risk is far from minimal.
Option D: Option D is incorrect; premature coronary calcification and dyslipidemia in a 29-year-old are not simply age-appropriate and unrelated — AAS directly contribute to both.
Option E: Option E is incorrect; the findings are not fully explained by erythrocytosis or reversible with phlebotomy alone; there are genuine structural (concentric hypertrophy, impaired diastolic function) and atherosclerotic components.
23. [CASE 6 — QUESTION 23]
Continuing with the same patient. As part of his evaluation, he undergoes endocrine and reproductive testing, which reveals small, soft testes, suppressed LH and FSH, and azoospermia on semen analysis. Which of the following best explains these reproductive findings?
A) Exogenous anabolic-androgenic steroids suppress the hypothalamic-pituitary-gonadal axis through negative feedback, lowering GnRH, LH, and FSH; the loss of LH-driven Leydig cell stimulation collapses intratesticular testosterone (producing testicular atrophy), and combined with FSH suppression this halts spermatogenesis, producing azoospermia.
B) Anabolic steroids directly stimulate LH and FSH secretion, and the resulting gonadotropin excess paradoxically causes azoospermia.
C) The azoospermia is caused by a physical obstruction of the vas deferens produced by anabolic steroid crystallization.
D) The findings reflect a primary testicular tumor unrelated to anabolic steroid use.
E) Anabolic steroids increase intratesticular testosterone far above normal, and this excess is what suppresses sperm production.
ANSWER: A
Rationale:
Option A is correct. Exogenous anabolic-androgenic steroids suppress the hypothalamic-pituitary-gonadal (HPG) axis through negative feedback, lowering GnRH pulsatility and pituitary LH and FSH secretion. The loss of LH-driven Leydig cell stimulation collapses intratesticular testosterone, producing testicular atrophy (small, soft testes), and combined with FSH suppression (which removes Sertoli cell support), this halts spermatogenesis and produces azoospermia. The suppressed LH and FSH in this patient are the signature of exogenous androgen-induced central suppression.
Option B: Option B is incorrect; anabolic steroids suppress (not stimulate) LH and FSH; his gonadotropins are low, not elevated.
Option C: Option C is incorrect; the azoospermia results from suppressed spermatogenesis, not physical obstruction from steroid "crystallization," which is not a real phenomenon.
Option D: Option D is incorrect; the constellation of suppressed gonadotropins, testicular atrophy, and azoospermia in a known AAS user reflects HPG suppression, not a primary testicular tumor.
Option E: Option E is incorrect; anabolic steroids lower (not raise) intratesticular testosterone by suppressing LH-driven Leydig cell stimulation; the fall in intratesticular testosterone is what impairs spermatogenesis.
24. [CASE 6 — QUESTION 24]
Continuing with the same patient. He has stopped all anabolic-androgenic steroids and now wishes to recover his endogenous testosterone production and fertility. Which of the following pharmacologic approaches is most rational to assist recovery of his suppressed hypothalamic-pituitary-gonadal axis?
A) Begin long-term high-dose exogenous testosterone, which will signal the testes to resume their own production through positive feedback.
B) Administer a GnRH antagonist to further block the axis and trigger a compensatory rebound in gonadotropin secretion.
C) Provide no intervention, since axis recovery is impossible after anabolic steroid use and any pharmacologic effort is futile.
D) Use human chorionic gonadotropin (an LH-receptor agonist that restores intratesticular testosterone) and/or a selective estrogen receptor modulator such as clomiphene (which blocks hypothalamic estrogen feedback to raise endogenous LH and FSH), thereby stimulating recovery of endogenous testosterone production and spermatogenesis.
E) Begin an aromatase inhibitor as the sole therapy, which will fully and reliably restore both testosterone and fertility in all cases without any other agent.
ANSWER: D
Rationale:
Option D is correct. After anabolic-androgenic steroids suppress the hypothalamic-pituitary-gonadal (HPG) axis, recovery can be assisted pharmacologically with agents that restart the axis. Human chorionic gonadotropin acts as an LH-receptor agonist on Leydig cells to restore intratesticular testosterone, and a selective estrogen receptor modulator such as clomiphene blocks hypothalamic estrogen receptor feedback to raise endogenous LH and FSH; these stimulate recovery of endogenous testosterone production and spermatogenesis (sometimes used together or sequentially).
Option A: Option A is incorrect; exogenous testosterone acts through negative (not positive) feedback and would further suppress the axis, worsening the suppression it is meant to reverse.
Option B: Option B is incorrect; a GnRH antagonist would deepen axis suppression rather than trigger a beneficial rebound.
Option C: Option C is incorrect; axis recovery is frequently achievable after AAS cessation, often assisted by recovery pharmacology, so intervention is not futile.
Option E: Option E is incorrect; an aromatase inhibitor alone is not a reliable, complete restorative therapy for all men; hCG and SERMs are the established approaches for assisting HPG axis and fertility recovery.
25. [CASE 7 — QUESTION 25]
A 73-year-old man with metastatic castration-resistant prostate cancer, maintained on a GnRH agonist, is started on enzalutamide after disease progression. His oncologist reviews how enzalutamide differs from earlier androgen receptor antagonists. Which of the following best describes enzalutamide's mechanism of action?
A) Enzalutamide lowers androgen synthesis by inhibiting CYP17A1, identical to the mechanism of abiraterone.
B) Enzalutamide is a second-generation non-steroidal androgen receptor antagonist that binds the androgen receptor with high affinity and additionally inhibits nuclear translocation of the androgen receptor-ligand complex and androgen receptor binding to DNA, producing more complete androgen receptor pathway blockade than first-generation agents such as bicalutamide.
C) Enzalutamide is a 5 alpha-reductase inhibitor that reduces conversion of testosterone to DHT in the prostate.
D) Enzalutamide suppresses pituitary LH secretion through progestogenic activity, lowering testicular testosterone to castrate levels.
E) Enzalutamide acts as an LH-receptor agonist on Leydig cells, paradoxically reducing tumor growth.
ANSWER: B
Rationale:
Option B is correct. Enzalutamide is a second-generation non-steroidal androgen receptor (AR) antagonist that binds the AR with high affinity (approximately 5 to 8 times that of bicalutamide) and, beyond competitive binding, also inhibits nuclear translocation of the AR-ligand complex and impairs AR binding to DNA and coactivator recruitment. These additional mechanisms produce more complete AR pathway blockade than first-generation agents such as bicalutamide, underlying its activity in castration-resistant disease.
Option A: Option A is incorrect; enzalutamide does not inhibit CYP17A1; that is the mechanism of abiraterone, which lowers androgen synthesis.
Option C: Option C is incorrect; enzalutamide is not a 5 alpha-reductase inhibitor; it acts at the androgen receptor, not by reducing DHT synthesis.
Option D: Option D is incorrect; enzalutamide does not suppress pituitary LH through progestogenic activity; it is an AR antagonist.
Option E: Option E is incorrect; enzalutamide is not an LH-receptor agonist (that describes hCG); it blocks the androgen receptor.
26. [CASE 7 — QUESTION 26]
Continuing with the same patient. During medication reconciliation, his oncologist notes a history of a prior seizure several years ago and a remote traumatic brain injury. This history prompts particular caution with enzalutamide. Which of the following best explains the central nervous system (CNS) concern specific to enzalutamide?
A) Enzalutamide raises the seizure threshold by enhancing GABA-A receptor activity, so a seizure history is actually a favorable indication for its use.
B) Enzalutamide causes seizures exclusively through a pharmacokinetic interaction that lowers anticonvulsant levels, with no intrinsic CNS effect of its own.
C) Enzalutamide has no CNS effects, and a seizure history is irrelevant to its use.
D) Enzalutamide acts as a negative allosteric modulator of GABA-A receptors, reducing inhibitory chloride conductance and lowering the seizure threshold; the seizure risk during therapy is approximately 0.5% per year, and a prior seizure history and CNS pathology (such as a remote traumatic brain injury) are predisposing factors that warrant careful benefit-risk assessment before initiating therapy.
E) Enzalutamide causes seizures by directly inducing cortical structural atrophy after a single dose, producing irreversible epileptogenesis.
ANSWER: D
Rationale:
Option D is correct. Enzalutamide acts as a negative allosteric modulator of the gamma-aminobutyric acid type A (GABA-A) receptor, reducing the receptor's chloride conductance in response to GABA and thereby lowering the seizure threshold. The seizure risk during enzalutamide therapy is approximately 0.5% per year, which led to its inclusion as a prominent warning in the prescribing information. A prior seizure history, CNS pathology such as a remote traumatic brain injury, and concurrent use of other threshold-lowering drugs are predisposing factors that warrant careful individualized benefit-risk assessment before starting enzalutamide.
Option A: Option A is incorrect; enzalutamide lowers (not raises) the seizure threshold by acting as a negative (not positive) allosteric modulator of GABA-A receptors, so a seizure history is a cautionary factor, not a favorable indication.
Option B: Option B is incorrect; the seizure risk reflects an intrinsic CNS pharmacodynamic effect (GABA-A negative allosteric modulation), not merely a pharmacokinetic interaction lowering anticonvulsant levels (although enzalutamide is also an enzyme inducer).
Option C: Option C is incorrect; enzalutamide does have CNS effects (fatigue, cognitive impairment, seizure risk), and a seizure history is clearly relevant.
Option E: Option E is incorrect; the seizure risk arises from a reversible GABA-A pharmacodynamic mechanism, not from cortical structural atrophy or irreversible epileptogenesis after a single dose.
27. [CASE 7 — QUESTION 27]
Continuing with the same patient. He takes several other medications, including a direct oral anticoagulant and a statin, both metabolized by hepatic enzymes. His oncologist reviews potential drug interactions with enzalutamide. Which of the following best describes a clinically important pharmacokinetic property of enzalutamide?
A) Enzalutamide is a potent inducer of CYP3A4 (and also induces CYP2C9, CYP2C19, and UGT enzymes), so it can lower the plasma concentrations and reduce the efficacy of co-administered drugs metabolized by these pathways; co-medications should be reviewed and dose-adjusted or substituted as needed.
B) Enzalutamide is a potent inhibitor of CYP3A4 that markedly raises the levels of co-administered substrates, increasing their toxicity.
C) Enzalutamide has no effect on hepatic drug-metabolizing enzymes and carries no clinically important pharmacokinetic interactions.
D) Enzalutamide is eliminated entirely unchanged by the kidney and therefore cannot participate in any hepatic enzyme-mediated drug interactions.
E) Enzalutamide selectively inhibits P-glycoprotein while having no effect on cytochrome P450 enzymes.
ANSWER: A
Rationale:
Option A is correct. Enzalutamide is a potent inducer of CYP3A4 and also induces CYP2C9 and CYP2C19 (and UGT enzymes). As an enzyme inducer, it can lower the plasma concentrations of co-administered drugs metabolized by these pathways — potentially reducing the efficacy of agents such as certain anticoagulants, statins, and many other substrates — so concomitant medications should be reviewed and dose-adjusted or substituted as needed.
Option B: Option B is incorrect; enzalutamide is an enzyme inducer, not a potent CYP3A4 inhibitor; it tends to lower (not raise) substrate concentrations.
Option C: Option C is incorrect; enzalutamide does affect hepatic drug-metabolizing enzymes (it is a significant inducer) and carries clinically important interactions.
Option D: Option D is incorrect; enzalutamide is not eliminated entirely unchanged by the kidney; it is hepatically metabolized and induces hepatic enzymes.
Option E: Option E is incorrect; enzalutamide's principal interaction profile is enzyme induction (CYP3A4, CYP2C9, CYP2C19, UGT), not selective P-glycoprotein inhibition with no CYP effect.
28. [CASE 7 — QUESTION 28]
Continuing with the same patient. After an initial response, his disease progresses on enzalutamide, and circulating tumor cell testing is positive for AR-V7. Which of the following is the most appropriate next step, and what is the underlying rationale?
A) Switch to a different androgen receptor antagonist such as darolutamide, which retains full activity against AR-V7-positive disease by binding the ligand-binding domain more tightly than enzalutamide.
B) Add exogenous testosterone to outcompete the variant receptor and restore sensitivity to androgen receptor-directed therapy.
C) Initiate taxane chemotherapy (docetaxel or cabazitaxel), because AR-V7 is a constitutively active androgen receptor splice variant lacking the ligand-binding domain that renders the tumor resistant to androgen receptor-directed agents (which act at that domain) and to agents that merely lower androgen availability; taxanes act on microtubules independently of androgen receptor status and therefore retain activity.
D) Switch to abiraterone alone, since lowering androgen synthesis effectively controls a ligand-independent AR-V7-driven tumor.
E) Discontinue all systemic therapy and proceed directly to hospice, since no therapy retains activity once AR-V7 is detected.
ANSWER: C
Rationale:
Option C is correct. AR-V7 is a constitutively active, truncated androgen receptor splice variant that lacks the C-terminal ligand-binding domain (LBD); it activates androgen-responsive transcription without ligand. Because it has no LBD, it is resistant to competitive androgen receptor antagonists (enzalutamide, apalutamide, darolutamide, bicalutamide), all of which act at the LBD, and it is not effectively controlled by abiraterone, which lowers androgen synthesis (depriving ligand does not suppress a receptor that needs no ligand). Taxane chemotherapy (docetaxel or cabazitaxel) acts on microtubules to disrupt mitotic and intracellular trafficking — independent of androgen receptor status — and therefore retains activity in AR-V7-positive disease, making it the appropriate next step.
Option A: Option A is incorrect; darolutamide also binds the LBD and cannot block a receptor lacking the LBD, so it does not retain activity against AR-V7-positive disease.
Option B: Option B is incorrect; adding testosterone to metastatic prostate cancer would stimulate androgen-responsive disease and is not a rational therapy for AR-V7-positive disease.
Option D: Option D is incorrect; abiraterone depletes androgen, which does not meaningfully suppress a ligand-independent, constitutively active AR-V7 receptor.
Option E: Option E is incorrect; AR-V7 positivity predicts resistance to androgen receptor-directed agents but not to taxanes, so effective systemic therapy remains available and proceeding directly to hospice is inappropriate.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.